Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Clinical Implications

Clinical Implications

Download PDF
https://doi.org/10.1161/HYP.0000000000000013
Hypertension. 2014;64:209
Originally published July 9, 2014
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Salt Sensitivity With Aging (page 391)
    • Sympathetic and Metabolic Effects of Gastrectomy (page 431)
    • Comparison of Antifibrotic Therapies (page 315)
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Salt Sensitivity With Aging (page 391)

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Salt sensitivity is defined as a significant decrease in blood pressure when dietary sodium intake is lowered. Salt-sensitive individuals have a higher risk for cardiovascular disease. The incidence of salt sensitivity increases with age, but the underlying mechanisms are not fully understood. A major player could be a sodium channel in the plasma membrane of vascular endothelium.

The epithelial sodium channel is known to regulate blood pressure via the resorption of Na+ and H2O in the kidney. This protein has recently been identified in vascular endothelium where it mediates intracellular sodium influx followed by stiffening of the endothelial cell cortex. The fact that stiff endothelial cells lack normal function such as adequate nitric oxide release strongly indicates a role of endothelial sodium channels in salt sensitivity and salt-associated cardiovascular diseases.

In this issue of Hypertension, endothelial sodium channel is identified as the mediator of endothelial salt sensitivity with aging. Quantification of endothelial sodium channel in ex vivo aortae of young and old mice revealed an age-related increase in channel expression. Endothelial stiffening, strictly depending on extracellular Na+, was aggravated.

Spironolactone, an aldosterone antagonist, and amiloride, a sodium channel blocker, reduced aging-dependent endothelial salt sensitivity. These classical diuretics, traditionally used to interfere with electrolyte transport in the kidneys, are suggested for the treatment of salt-sensitive hypertension and salt-associated cardiovascular disease in the elderly.

Sympathetic and Metabolic Effects of Gastrectomy (page 431)

Sympathetic activation represents a pathophysiological hallmark of human obesity, contributing to the elevated cardiovascular risk profile of this clinical condition. Bariatric surgery has been previously shown to exert favorable effects on cardiometabolic function, reducing body weight and improving insulin sensitivity. Whether sympathetic neural function is also favorably affected by the intervention, particularly in the long term, is still largely unknown. The present study assessed the long-term effects (1 year) of sleeve gastrectomy on muscle sympathetic nerve traffic directly, recorded via the microneurographic technique, and the relationship with concomitant cardiometabolic changes. In 10 severely obese patients who underwent sleeve gastrectomy, we found that bariatric surgery decreased body mass index by an average of 10.8 kg/m2 and muscle sympathetic nerve activity by 38% while improving baroreflex control of the circulation. These favorable neuroadrenergic and reflex effects (which were not detected in the control group not undergoing surgery) were accompanied by a sustained reduction in circulating plasma leptin levels and by an improvement in insulin sensitivity. Taken together, these findings provide evidence that weight loss induced by sleeve gastrectomy is accompanied by sympathoinhibition, which may participate in the improvement in cardiometabolic risk profile observed after bariatric surgery.

Comparison of Antifibrotic Therapies (page 315)

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Fibrosis is a pathological end point of both hypertensive and nonhypertensive heart disease and a significant contributor to cardiac dysfunction and failure. The inability of the myocardium to undergo coordinated healing from injury, because of irreversible cardiomyocyte loss and a disproportionate accumulation of (myo)fibroblasts, leads to focal scarring, endocardial and interstitial fibrosis, which abets myocardial stiffening, and abnormalities in coronary reserve and cardiac contractility. Because angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers have limited antifibrotic actions compared with their blood pressure–lowering effects, these frontline therapies are unable to effectively protect from scarring-related end-stage organ failure. Hence, novel strategies that target collagen turnover and organization, while augmenting the actions of ACEi and angiotensin receptor blockers, may offer greater potential benefits. The hormone relaxin has rapid cardioprotective and antifibrotic actions, disrupting transforming growth factor-β1 signaling and collagen synthesis by myofibroblasts experimentally, regardless of pathogenesis. Despite this, the effects of relaxin on scarring have never been compared with current frontline treatments. In this issue of Hypertension, Samuel et al demonstrated that serelaxin (recombinant human relaxin 2) was more efficacious than optimal enalapril (ACEi) treatment in a murine model of cardiomyopathy. Combining serelaxin and enalapril reduced cardiac fibrosis by at least double that of enalapril alone in both preventative and therapeutic strategies. Although studies in other models are required, the clinical implications of these findings are that serelaxin may not only be a better antifibrotic than ACEi for nonhypertensive heart disease, but in combination may also enhance the antifibrotic efficacy while retaining the blood pressure–lowering effects of ACEi in hypertension-related disorders.

  • © 2014 American Heart Association, Inc.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
August 2014, Volume 64, Issue 2
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Salt Sensitivity With Aging (page 391)
    • Sympathetic and Metabolic Effects of Gastrectomy (page 431)
    • Comparison of Antifibrotic Therapies (page 315)
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Clinical Implications
    Hypertension. 2014;64:209, originally published July 9, 2014
    https://doi.org/10.1161/HYP.0000000000000013

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Clinical Implications
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Clinical Implications
    Hypertension. 2014;64:209, originally published July 9, 2014
    https://doi.org/10.1161/HYP.0000000000000013
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured